Datasets and metadata supporting the published article: Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models

The study investigated the effects of LG268, a Retinoid X Receptor (RXR) agonist, as an immune modulator in the tumor microenvironment of two genetically and histologically distinct mouse models of breast cancer.
Data access: The datasets supporting all the figures in this published article are publicly available in the figshare repository (as part of this data record, https://doi.org/10.6084/m9.figshare.9944942) and in the supplementary files of the article.

Ethical approval: All animal studies were done in accordance with protocols approved by the Institutional Animal Care and Use Committee at Michigan State University.
Study aims and methodology: The present study aimed to examine the immunomodulatory effects of LG268, an RXR agonist, in MMTV-Neu and PyMT mouse models of human epidermal growth factor receptor 2 (HER2) positive breast cancer and triple negative breast cancer (TNBC), respectively.The following cell lines were cultured: RAW 264.7 mouse macrophage-like (ATCC) cells, E18-14C-27 cells, THP-1 (ATCC) cells, SK-BR-3 (ATCC) cells and THP-1 cells.Western blotting was performed on whole cell lysates of cells treated with drugs. Western blotting was also performed on homogenised tumors or mammary glands of mice treated with drug or a control diet.Flow cytometry was carried out on cells derived from the tumor, mammary gland and spleen removed from MMTV-neu or MMTV-PyMT female mice. For more details on the methodology, please see the related article.
Dataset descriptions: The datasets supporting the figures in the published article are described in table Leal et. al.xlsx and are part of this data record. All four datasets are in .xlsx file format.
Figure 7 dataset.xlsx: Data on the expression levels of PD-L1 in cancer cells and macrophages after treatment with LG268 or bexarotene.
MMTV-Neu immune and protein data.xlsx: Data on MMTV-Neu mice including tumor and spleen weight, tumor immune cell populations, spleen immune cell populations and mammary gland immune cell populations.
PCR and flow CD3 activation.xlsx: Quantitative PCR data to determine the levels of FOXP3 and data on CD3 T cells stimulated with anti-CD3 and treated with LG268. Activation of CD4 and CD8 was evaluated by flow cytometry
PyMT data sets.xlsx: Data on PyMT mice, including tumor and spleen weight, tumor immune cells, mammary gland immune cells and spleen cells.